jeudi 19 avril 2018

Onco Actu du 19 avril 2018

1. Biologie

How Kidney Cancer Evolves [The Scientist]

Science Surgery: ‘Do we all have potentially cancerous cells in our bodies?’ [Cancer Research UK]

Cancer Evolutionist: A Profile of Charles Swanton [The Scientist]

4. Dépistage, diagnostic et pronostic

Scientists create a biomedical tattoo to monitor for a sign of cancer [STAT]

Implant will show when cancer is present by generating artificial mole on skin [The Telegraph]

4.10 Dép., diag. & prono. - Poumon

Penn Researcher Co-Directs National Lung Cancer Screening Center [Penn Medicine]

4.2 Dép., diag. & prono. - Génome

ACMG 2018 – “There is Still So Much We Have to Learn” [enlightenbio]

5. Traitements

Cancer treatment in the last 6 months of life: when inaction can outperform action [ecancermedicalscience]

5.1 Traitements - Pré-clinique

Gene Mapping Lays Groundwork for Precision Chemotherapy [UCSF]

5.12.3 Immunothérapies-combinaisons

'Jury still out' on pairing up cancer immunotherapies: Merck & Co. science exec [S&P Global Market Intelligence]

5.12.5 Immunothérapies - Pharma

Grid Therapeutics raises $5M for complement-activating I-O drug [FierceBiotech]

Surface Oncology’s Upsized IPO Reels in $108M for Lead Cancer Drug [Xconomy]

5.12.8 Immunothérapies - Economie

Cancer hospitals push for Medicare CAR-T payments [Axios]

5.2 Pharma

Lilly highlights 'relentless' women in first ads for breast cancer med Verzenio (abemaciclib) [FiercePharma]

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review [BMS]

5.2.2 Pharma - Fusions & Acquisitions

On the hunt for R&D deals, GlaxoSmithKline raids Roche’s executive cupboard again [FierceBiotech]

GlaxoSmithKline’s Hal Barron poaches Genentech’s top cancer drug dealmaker for his new R&D team [EndPoints]

GSK grabs Roche cancer expert to lead pharma pipeline deals [Reuters]

5.2.3 Pharma - économie

Has biopharma over-invested in cancer R&D? [Jay Bradner - Novartis]

5.3 Traitements - FDA, EMA, NICE...

FDA chief Scott Gottlieb promises to streamline drug development pathway for biopharma [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA,...)

US FDA approves Tagrisso as 1st-line treatment for EGFR-mutated non-small cell lung cancer [AstraZeneca]

AstraZeneca wins expanded OK to use Tagrisso in frontline lung cancer niche, spurring hope of hitting $3B sales goal [EndPoints]

AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug [Reuters]

Brentuximab Approved for Initial Treatment of Advanced Hodgkin Lymphoma [NCI]

5.4 Traitements - Economie

Three Steps Toward a More Sustainable Path for Targeted Cancer Drugs [JAMA]

5.9 AACR

Cancer Wrap: Blueprint, Checkmate, More AACR News & Phase 3 Blues [Xconomy]

5.9.4 AACR - poumon

Coke or Pepsi: Comparing anti PD-1 agents at AACR 2018 [OBR Blog]

Merck Immunotherapy Drug Shines In Lung Cancer Study [NPR]

A New Treatment With Immunotherapy Brings A Moment Of Hope For Patients With Lung Cancer [Dr. Len's Blog]

5.9.9 AACR - immunothérapies

AACR Annual Meeting 2018: Novel Immunotherapy Combinations to Combat Resistance to Checkpoint Inhibition [Cancer Research Catalyst]

At AACR, Immuno-Oncology Clinical Trials Offer Mixed Messages on Predictive Biomarkers [Genome Web]

Turning cold tumors hot, Checkmate Pharma outlines its initial success story at #AACR18 [EndPoints]

6.1 Observation

Married People Less Likely to Die From Melanoma [NY Times]

6.5 Médecines alternatives

GPs at one in 12 practices are still prescribing homeopathic treatments for their patients – even though there’s no scientific evidence it works [Daily Mail]

6.6 Publications

Preprints in medical research: Progress and principles [PLoS Medicine]

6.7.1 IA/bioinformatique

Google's New AI Head Is So Smart He Doesn't Need AI [Wired]